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Accepted 13 November 2018Bilberries, Vaccinium myrtillus, have a high content of phenolic compounds including
anthocyanins, which could provide cardiometabolic health benefits following acute
myocardial infarction (AMI). We hypothesized that standard medical therapy
supplemented with freeze-dried bilberry after AMI would have a more beneficial effect on
cardiovascular risk markers and exercise capacity than medical therapy alone. Patients
were allocated in a 1:1 ratio within 24 hours of percutaneous coronary intervention in an 8-
week trial either to V myrtillus powder (40 g/d, equivalent to 480 g fresh bilberries) and
standard medical therapy or to a control group receiving standard medical therapy alone.
High-sensitivity C-reactive protein and exercise capacity measured with the 6-minute walk
test were the primary biochemical and clinical end points, respectively. Fifty subjects
completed the study. No statistically significant difference in high-sensitivity C-reactive
protein was detected between groups. The mean 6-minute walk test distance increased
significantly more in the bilberry group compared to the control group: mean difference
38 m at follow-up (95% confidence interval 14-62, P = .003). Ex vivo oxidized low-density
lipoprotein was significantly lowered in the bilberry group compared to control, geometric
mean ratio 0.80 (95% confidence interval 0.66-0.96, P = .017), whereas total cholesterol and
low-density lipoprotein cholesterol did not differ significantly between groups.
Anthocyanin-derived metabolites in blood increased significantly in the bilberry groupKeywords:
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mean; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; hs-CRP, high-
rtile range; LDL, low-density lipoprotein; NSTEMI, non–ST-segment elevation myocardial
ention; STEMI, ST-segment elevation myocardial infarction.
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14 N U T R I T I O N R E S E A R C H 6 2 ( 2 0 1 9 ) 1 3 – 2 2during the intervention and were different after 8 weeks between the bilberry group and
control. Findings in the present study suggest that bilberries may have clinically
relevant beneficial effects following AMI; a larger, double-blind clinical trial is warranted
to confirm this.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bilberries contain vitamin C, vitamin K, folic acid, carotenoids,
and dietary fiber in varying proportions depending on species [1].
They are also rich in anthocyanins (ACs), a flavonoid subclass
which is responsible for the red-blue color of bilberries, and have
been the subject of research with respect to their health benefits
properties [2,3]. It has been suggested that consumption of
flavonoids, and in particular ACs, found in berries may reduce
the risk of death from cardiovascular disease (CVD) [4-7]
potentially due to beneficial effects on platelet function [8],
increased high-density lipoprotein (HDL) cholesterol [6], inflam-
mation [9], and lowering of blood pressure [8,10]. Bilberries also
contain other phenolic compounds such as cinnamic and
benzoic acids and flavonols which also have been associated
with beneficial outcomes [11].
Plants commonly known as blueberry (Vaccinium
corymbosum, V ashei, and V angustifolium) and bilberry (V
myrtillus) are often considered the same. Despite similarities,
the berries differ in taste, pulp color, and nutritional content.
The dominant ACs differ, and the quantity of ACs in bilberries
is more than twice that in blueberries [12]. The AC content
seems to be higher in wild plants compared to cultivated
[13,14]. In vitro studies and studies in healthy subjects have
demonstrated cardioprotective effects of bilberry [9,15,16].
The ACs in bilberries show antioxidant properties in vitro in
vascular endothelium and vascular smooth muscle even at
low concentrations [17]; however, the biological relevance of
direct antioxidant effects of ACs for cardiovascular health in
humans is not established [18]. ACs are further reported to
reduce inflammation in people with metabolic syndrome [9]
and those at increased risk for CVD [15]. The antioxidative and
anti-inflammatory effects of ACs from bilberries could im-
prove recovery from exercise [19-21] and potentially affect
vasoactive properties that could increase aerobic exercise
performance [22,23].
Evidence that dietary factors can prevent and combat
CVD is accumulating, and strong evidence supports a positive
effect of Mediterranean diets [24]. Similarly, an accumulating
number of studies show similar benefits of a healthy Nordic
diet, where Nordic berries such as bilberries have typically
been included [25-28]. Clinical research of nutritional supple-
ment intervention following acute disease is scarce. We
designed an open-label randomized clinical trial to test the
efficacy of bilberry V myrtillus supplement initiated within
24 hours of percutaneous coronary intervention (PCI) for
acute myocardial infarction (AMI). We hypothesized that
standard medical therapy supplemented with freeze-dried
bilberry after AMI would have a more beneficial effect on
cardiovascular risk markers and the outcome of a 6-minute
walk test (6MWT) than medical therapy alone.2. Methods and materials
2.1. Study objective and design
The “Bilberry as a Dietary Supplement after Myocardial
Infarction” (BEARSMART) trial was a prospective, open-label,
randomized, controlled clinical trial stratified for type of
infarction and sex. From June 2014 to May 2015, subjects were
recruited from patients referred to Örebro University Hospital
for PCI after ST-segment elevation myocardial infarction
(STEMI) or non–ST-segment elevation myocardial infarction
(NSTEMI). Following informed consent, individuals were allo-
cated in a 1:1 ratio within each stratum to bilberry supplemen-
tation or to no dietary intervention, in addition to standard
medical therapy. Clinical assessmentwas conducted, with data
and blood samples collected at baseline and after 8 weeks. The
trial was approved by the regional ethics review board in
Uppsala, Sweden (Drn: 2013/311) and registered in a clinical
trials registry (ClinicalTrials.gov identifier: NCT01958034).
2.2. Patient inclusion and exclusion criteria
STEMI was defined as chest pain suggestive of myocardial
ischemia for at least 30 minutes before hospital admission,
time from onset of symptoms of less than 24 hours, and an
electrocardiogram with new ST-segment elevation in 2 or
more contiguous leads of ≥0.2 mV in leads V2-V3 and/or
≥0.1 mV in other leads, or a probable new-onset left bundle-
branch block. NSTEMI was defined as a combination of onset
of symptoms such as central chest pain or aggravated angina
pectoris, with or without electrocardiographic changes, with
ST-segment depression or an inverted T wave and a rise of
troponin I above the hospital-established margin of 0.070 μg/L.
Five months into the study, high-sensitivity analysis of
troponin I was introduced, and the established margin was
changed to 0.016 μg/L for females and to 0.032 μg/L for males.
Exclusion criteria were emergency coronary artery bypass
grafting; inability to provide informed consent; age <18 years;
daily intake, or the intent to initiate daily intake, of bilberry in
some form (fresh berries, powder, soup, etc); or previous
randomization in the BEARSMART trial. After providing written
informed consent, patients who fulfilled inclusion criteria
with no exclusion criteria were randomized according to a
computer-generated random-number sequence.
2.3. Patient instructions
Subjects randomized to bilberry supplementation were
instructed to use a dedicated 25-mL spoon, corresponding to
~13.3 g, to measure a dose of dehydrated bilberry to take with
meals 3 timesaday, for a total of 40 g of powder per day, equaling
Table 1 – Anthocyanins in V myrtillus powder
ACs Mean (mg/g) (SD)
Peonidin-3-galactoside 3.0 ± 0.01
Peonidin-3-glucoside 0.00
Cyanidin-3-galactoside 3.11 ± 0.04
Cyanidin-3-glucoside 0.00
Cyanidin-3-arabinoside 1.20 ± 0.01
Delphinidin-3-galactoside 3.68 ± 0.03
Delphinidin-3-glucoside 0.16 ± 0.01
Pelargonidin-3-galactoside 0.87 ± 0.01
Pelargonidin-3-glucoside 0.01 ± 0.01
Petunidin-3-galactoside 4.7 ± 0.02
Malvidin-3-galactoside 6.26 ± 0.04
15N U T R I T I O N R E S E A R C H 6 2 ( 2 0 1 9 ) 1 3 – 2 2approximately 480 g of fresh berries. The powder (Immune,
Skellefteå, Sweden, http://www.immun.se/) contained several
ACs (Table 1) andother phenolic compounds reported before [29].
Nutritional value of the powderwas as follows (per 100 g): energy
377 kcal/1600 kJ, protein 5 g, carbohydrates 82 g (sugars 30 g,
fructose 19 g, glucose 11 g, sucrose <2 g), dietary fiber 25 g
(insoluble 19 g, soluble 6 g), fat 4 g, and ACs 2250 mg. Subjects
were instructed to take thepowder uncooked,mixedwith food or
beverage. A three-times-per-day intake was considered appro-
priate given the relatively shortmetabolic half-life ofACs in blood
[30]. The bilberry intervention was initiated within 24 hours of
PCI, and the trial continued for 8 weeks. Subjects in the control
group were instructed not to consume bilberry or blueberry.2.4. Examinations and blood tests
An overview of examinations carried out during the study is
shown in Fig. 1. All patients underwent the following examina-
tions at baseline and at 8 weeks:
2.4.1. Six-minute walk test
The purpose of a 6MWT was to assess exercise capacity by
measuring the distance the subjectwas able towalk in 6minutes
on a hard, flat surface [31]. Tests were carried out by qualified
physiotherapists blinded to the type of study intervention.
2.4.2. Transthoracic echocardiography (CX50; Philips, Bothell,
WA, USA)
At baseline, left ventricular systolic function, expressed as global
ejection fraction in percent, was evaluated by echocardiographyFig. 1 – A schematic of examinations carried out during theby the discharging physician. The procedure was repeated after
the 8-week. intervention by an experienced echocardiography
technician blinded to results of the initial examinations. The
physician and the technician were blinded to the type of
intervention. Two-dimensional biplane Simpson method was
used for ejection fraction assessment.
2.4.3. Heart rate and blood pressure
Heart rate and blood pressure were measured at baseline and
after the 8-week. intervention by an automatic sphygmoma-
nometer after 15 minutes of rest.
2.4.4. Analyses of blood samples
Venous blood was drawn from the arm after 10 minutes of
rest by an experienced nurse. Inflammatory markers, lipid
profile, glycosylated hemoglobin (HbA1c), and heart function
markers were analyzed at the accredited Clinical Chemical
Laboratory at Örebro University Hospital, Sweden. Blood
samples were centrifuged immediately and stored at −70°C
until further analyses.
Analysis of phenolic compounds in berry powder and in
blood samples was conducted to assess compliance on the
presumption that the concentrations of selected phenolic
compounds would be higher in the bilberry group. AC-derived
metabolites in blood associated with bilberry consumption
were analyzed by a validated method combining liquid
chromatography with mass spectrometry and authentic
standards as previously described [32]. Total antioxidant
activity of serumwas evaluated at the Department of Ecology,
Physiology, and Ethology, Hubert Curien Pluridisciplinary
Institut, University of Strasbourg, France, using the Radicaux
Libre Kit biological test based on free radical-induced hemo-
lysis (M Prost, Spiral/Kirial International, Strasbourg, France)
[33-36]. Standard whole blood (Biomérieux, Marcy l'Etoile,
France), with and without the presence of diluted serum
samples, was exposed to organic free radicals produced at
37°C under air atmosphere from thermal decomposition of
2,2’azobis (2-amidinopropane) dihydrochloride. Hemolysis
was recorded in a 96-well microplate reader by measuring
the optical density decay (KRL Reader, Spiral/Kirial Interna-
tional). Results were expressed as the time required to reach
50% of maximum hemolysis (half-hemolysis time, T1/2 in
minutes), an indicator of blood resistance to free radical
attack. The antioxidant activity of serum was defined as the
percent serum-mediated increase of the half-hemolysis timecourse of the study. BP, blood pressure; HR, heart rate.
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ized in equivalent mmol Trolox per liter of serum. Analysis of
serum-oxidized low-density lipoprotein (LDL) was performed at
Uppsala University Hospital, Sweden, with sandwich enzyme-
linked immunosorbent assay (Mercodia, Uppsala, Sweden)
according tomanufacturer's instructions. In an initial incubation
step, oxidized LDL reacted with antioxidized LDL antibodies
bound to a microtitration well. After washing, a peroxidase-
conjugated anti–human apolipoprotein B antibody recognizes
the oxidized LDL bound to the solid phase. A substrate solution
was subsequently added. The reaction was stopped by adding
acid, and the absorbance was measured in a SpectraMax 250
(Molecular Devices, Sunnyvale, CA, USA). The total coefficient of
the assay was approximately 5%. The assay was performed
blinded, without knowledge of the clinical diagnosis or random-
ization. Analysis of high-sensitivity C-reactive protein (hs-CRP)
(Advia 1800; Siemens, Munich, Germany), total cholesterol
(Vitros; Ortho, Rochester, NY, USA), HDL cholesterol (Vitros;
Ortho), LDL cholesterol (Vitros; Ortho), triglycerides (Vitros;
Ortho), HbA1c (Tosoh, Rochester, NY, USA ), brain natriuretic
peptide (Architecht; Abbott, Lake Forest, IL, USA), troponin I
(Architecht; Abbott, Lake Forest, IL, USA), and high-sensitivity
troponin I (Architecht; Abbott, Lake Forest, IL, USA) was
performed at Örebro University Hospital, Örebro, Sweden,
according to manufacturers' instructions.
2.4.5. Quality of life questionnaire
To evaluate quality of life, subjects were asked to complete a
European Quality of Life-5 Dimensions (EQ5D) questionnaire
[37] at baseline and at 8 weeks.
2.5. End points and definitions
Our primary biochemical end point was differences between
groups in level of hs-CRP, as a marker of inflammation after
the 8-week. intervention. Secondary biochemical end points
were lipid levels, oxidative stress markers, and heart function
indicators after 8 weeks. of intervention. Our primary clinical
end point was the 6MWT outcome, whereas secondary
clinical end points included left ventricular systolic function,
resting blood pressure, resting heart rate, and EQ5D outcome.
2.6. Statistics
We based sample size calculation primarily on the findings of
Karlsenet al [15], a clinical studyofVmyrtillusandCVDriskwhere
consumption of bilberry juice for 4weeks reduced hs-CRP by 23%
compared to baseline median change of −0.30 mg/L, whereas, in
a placebo group, an increase of 15% (median change 0.15 mg/L)
was seen (P = .027). Assuming comparable effects among our
subjects and a standard deviation of hs-CRP of 0.5 mg/L, we
needed to study 21 patients in the bilberry group and 21 patients
in the control group to be able to reject the null hypothesis that
the experimental and control treatments were identical, with a
probability (power) of .80. The type I error probability associated
with testing the null hypothesis was 0.05 (http://clincalc.com/
Stats/SampleSize.aspx). To control for dropouts, we aimed to
include 25 subjects in each group.
Clinical, biochemical, and compliance outcome variables
were evaluated with a random intercept linear mixed model,a model that is similar to a 2-way analysis of variance for
repeated measurements. Study groups, time (pre, post), and
the interaction groups*time were fixed factors. The model
estimated marginal mean differences of outcome between
pre and post within the study groups, and changes in mean
differences between the study groups, all reported with 95%
confidence intervals (CIs). Log10 transformation was used for
outcome variables that showed better fit to the normal
distribution assumption after transformation. These variables
are reported with geometric means and interquartile range
(IQR) and geometric mean ratios with 95% CI. A geometric
mean ratio of 1 implies nomean difference between the study
groups (or pre to post), a geometric mean ratio of 1.5 implies a
50% higher mean, whereas a geometric mean ratio of 0.9
implies a 10% lower mean in bilberry compared to control
group. For compliance variables with values that fell below
the limit of detection, an estimated concentration of 50% of
the detection limit was used. As some of the compliance
outcome variables had many values below the limit of
detection, these results should be interpreted with caution.
A P value lower than .05 was considered statistically signif-
icant. All analyses were performed with the use of IBM SPSS
Statistics 22 (Armonk, NY, USA).3. Results
Of 60 candidate patients, 50 (42 male) of median age 68 years
(IQR 61-72) completed the study (Fig. 2). Five patients declined
participation, 4 withdrew consent, and 1 patient randomized
to intervention was excluded after stating that he had not
consumed the bilberry powder. Results were analyzed ac-
cording to a modified intention-to-treat analysis that in-
cluded all patients who consumed bilberry powder at least
once (active arm) and all patients allocated to no intervention.
The baseline characteristics were well balanced as shown in
Table 2. The mean atorvastatin dose in the bilberry group
(excluding 1 patient receiving simvastatin) was 75.8 ± 14.1 mg
at baseline and 76.7 ± 11.1 mg at 8 weeks. The control group
received 79.2 ± 13.9 mg at baseline and 74.2 ± 21.2 mg at
8 weeks. The biochemical outcomes are presented in Table 3.
The primary biochemical outcome, hs-CRP, evaluated on log
scale, was not significantly different between groups after the 8-
week intervention: geometric mean (gmean) ratio 1.07 (95% CI
0.52-2.18). However, the bilberry group had a significantly lower
gmean at 8 weeks compared to baseline, 0.40 (95% CI 0.24-0.66),
and the control group, 0.38 (95%CI 0.23-0.62). No differenceswere
found in total cholesterol (mean difference −0.6, 95% CI −1.4 to
0.3, P = .17) or LDL cholesterol (gmean ratio 0.80, 95% CI 0.63-1.03,
P = .08) between study groups, but significant reductions in both
total and LDL cholesterol were found from baseline to after 8
weeks of intervention in the bilberry group (Table 3). Theoxidized
LDL was significantly lowered (~20%) in the bilberry compared to
control group: gmean ratio 0.80, 95% CI 0.66-0.96, P = .017. Other
biochemical outcome variables, including antioxidant activity,
changed numerically in favor of bilberry administration, but
differences were not statistically significant (Table 3).
In the bilberry group, the mean distance covered in the
6MWT increased significantly from 439 ± 115 m at baseline to
520 ± 136 m at 8 weeks, which was significantly greater
Fig. 2 – Study design.
17N U T R I T I O N R E S E A R C H 6 2 ( 2 0 1 9 ) 1 3 – 2 2increase than found in the control group, baseline 475 ±
103 m to 522 ± 108 m, resulting in a mean difference between
groups of 38 m (95% CI 14-62, P = .003) (Table 4). No other
clinical parameters changed significantly in bilberry com-
pared to control group.
Measures of AC-derived metabolites showed a signifi-
cantly higher increase of gallic acid, vanillic acid-4-O-sulfate,Table 2 – Baseline characteristics of subjects
Bilberry Control
n 25 25
Age, y median (IQR) 66 (62-71) 68 (62-74)
Female sex n (%) 5 (20.0) 3 (12.0)
Diabetes mellitus n (%) 6 (24.0) 6 (24.0)
Current smoker n (%) 4 (16.0) 5 (20.0)
Ex-smoker n (%) 9 (36.0) 6 (24)
BMI <25 n (%) 6 (24.0) 7 (28.0)
BMI ≥25 n (%) 19 (76.0) 18 (72.0)
Previous MI n (%) 5 (20.0) 5 (20.0)
Previous PCI n (%) 7 (28.0) 9 (36.0)
Previous CABG n (%) 0 (0.0) 1 (4.0)
STEMI n (%) 14 (56.0) 14 (56.0)
NSTEMI n (%) 11 (44.0) 11 (44.0)
β-Blocker n (%) 24 (96,0) 22 (88.0)
Ticagrelor n (%) 23 (92.0) 21 (84.0)
Clopidogrel n (%) 2 (8.0) 4 (16.0)
ASA n (%) 24 (96.0) 25 (100.0)
ACE inhibitor/ARB n (%) 22 (88.0) 22 (88.0)
NSAID n (%) 2 (8.0) 0 (0.0)
Statin n (%) 25 (100) 25 (100)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blocker; ASA, acetylsalicylic acid; BMI, body mass index; CABG,
coronary artery bypass graft; MI, myocardial infarction; NSAID,
nonsteroidal anti-inflammatory drug.p-coumaric acid, andcaffeic acid 4-β-D-glucuronide in thebilberry
compared to the control group. A higher increase inmeasures of
gallic acid, vanillic acid-4-O-sulfate, 3-hydroxyphenyl acetic acid,
p-coumaric acid, caffeic acid 3-β-D-glucuronide, and caffeic acid
4-β-D-glucuronide was detected in the plasma after the 8-week
intervention in the bilberry group compared to baseline (Supple-
mental Table S1). No adverse events were reported or observed
with bilberry supplementation.4. Discussion
Although the primary biochemical end point, hs-CRP, did not
change with bilberry compared to control group, we found a
clinically relevant significant effect on the secondary end
point of oxidized LDL. We found a significant improvement in
our primary clinical end point, 6MWT, with significantly
improved walking distance after bilberry compared to control.
To the best of our knowledge, an improvement in exercise
capacity with berry consumption in patients with AMI has not
previously been reported. A study on beetroot juice showed
increased submaximal endurance in older patients with heart
failure [38]. Our findings for the biochemical outcomes were
in partial agreement with results of a recent meta-analysis of
clinical trials of bilberry supplements in mostly healthy
humans that demonstrated reduction in LDL and increase in
HDL cholesterol [39]. Oxidized LDL, embedded in arterioscle-
rotic plaques [40], has been reported to decrease after
supplementation with delphinidin [41], an AC found in
bilberry [42]. Oxidized LDL is associated with all stages of
atherosclerosis and to comorbidities linked with CVD, such as
diabetes mellitus, hypertension, and obesity [43]. Therefore,
we speculate that bilberry could have a role in supplementing
medical therapy.
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All patients in this study were treated with statins
(3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors).
The bilberry intervention was associated with a statistically
significant reduction in oxidized LDL cholesterol, but total
cholesterol andLDLcholesterol showednonsignificantdifference
from standard therapy. Antioxidant capacity did not differ
between groups. However, the lipid-lowering effect of bil-
berry could be partly explained by the high quantity of ACs
[12]. We found significant correlations between LDL choles-
terol and oxidized LDL with levels of ACs after the 8-week
intervention, indicating a possible dose-response relation-
ship with cholesterol levels and AC in bilberries (see online
supplement Table S1). High quantity of AC has been reported
to affect mitochondria [44] and activate AMP-activated
protein kinase, which leads to phosphorylation of acetyl-
CoA carboxylase and thereby an increased fatty acid oxida-
tion [45]. In addition to ACs, other flavanol compounds
in bilberries having pleiotropic effects might contribute to
cholesterol lowering [46,47]. Hs-CRP did not differ between
groups at 8 weeks, although some dietary flavonoids have
been associated with a lower concentration of inflammatory
biomarkers [48]. Our patient population showed a high
inflammatory burden at baseline, and the natural course of
the disease, aided by statin treatment, may have reduced the
hs-CRP to a level beyond which bilberry had no effect. ACs
may increase exercise tolerance and could partly explain
improvement in 6MWT in the intervention group [49,50].
4.2. Strengths and limitations
In contrast to most previous studies using healthy individ-
uals, we initiated intervention with bilberry in a well-defined
patient group following AMI. Bilberry administration was
initiated within 24 hours of PCI at a vulnerable and critical
clinical phase [51,52]. This is an important study strength. The
study was originally designed as a randomized, double-blind,
placebo-controlled trial. However, at enrolment of 8 subjects,
3 complained of gastrointestinal distress. The placebo powder
(Gold Coast Ingredients, Inc, Los Angeles, CA, USA; blueberry
flavoring EU0548) was identified as the source of the problem,
and the study was terminated and decoded. The study was
redesigned as open label with a nondietary intervention arm
and no placebo. After ethics approval, the study was
reinitiated with new subjects. No results from the initial
double-blind trial were included in this report. We acknowl-
edge that an open-label design is methodologically weaker, a
factor for which we attempted to control by including
biochemical assessment of compliance. Our study was
small, and significant findings were in secondary outcome
variables. Because patients were aware of their treatment
allocation, our primary clinical outcome, 6MWT, was prone to
ascertainment bias; thus, the results of this test should be
interpreted with caution.
4.3. Conclusions
We found no effect of an 8-week treatment of bilberry powder
as a supplement to standard therapy post AMI on the primarybiochemical end point, hs-CRP, but we found a significant
improvement in 6MWT. Moreover, we found that blood lipid
profiles were altered within the bilberry group of a magnitude
that could potentially translate into a relevant reduction in
future CVD events in a better powered study. Larger placebo-
controlled studies addressing hard clinical end points are
needed to determine whether bilberry, V myrtillus, derivatives
have practical use in the treatment of CVD.Acknowledgment
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